<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645099</url>
  </required_header>
  <id_info>
    <org_study_id>CR013189</org_study_id>
    <secondary_id>R076477SCH3020</secondary_id>
    <nct_id>NCT00645099</nct_id>
  </id_info>
  <brief_title>A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia</brief_title>
  <official_title>A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag International NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen-Cilag International NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this 6 month study is to compare the metabolic effects of paliperidone ER and
      olanzapine in patients with schizophrenia, using the ratio of the concentration of lipids
      (triglycerides (TG)) in the blood to the concentration of good cholesterol (high density
      lipoproteins (HDL)) in the blood as the primary parameter. Approximately 456 adult patients
      will participate in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized (study medication is assigned by change) open-label,
      parallel-group, multicenter, 6 month study to compare the metabolic effects of paliperidone
      ER and olanzapine in patients with schizophrenia using the ratio of the concentration of
      lipids (triglycerides) in the blood to the concentration of good cholesterol (high density
      lipoproteins (HDL)) as the primary parameter. Secondary objectives include evaluation of
      additional parameters related to the total of the actions of the body to keep it alive
      (metabolic endpoints) and demonstration of non-inferiority of paliperidone ER versus
      olanzapine in efficacy as measured by Positive and Negative Syndrome Scale (PANSS). Patients
      previously treated with any oral antipsychotic, except those treated with paliperidone ER,
      olanzapine or clozapine during the last 6 months, can be enrolled and will be treated with
      paliperidone ER (6 to 9 mg/day) or olanzapine (10 to 15 mg/day). Patients will be divided
      into groups according to the metabolic effects of their previous antipsychotic medication
      (medication that does not increase body weight vs. medication that increases body weight).
      Throughout the study flexible dosing is allowed based on the investigator discretion. A study
      treatment period of 6 months is planned for all patients. Medication to treat symptoms like
      confusion, blurred vision, constipation, dry mouth, light-headedness, difficulty starting and
      continuing to urinate, and loss of bladder control may continue up to four weeks and should
      then be tapered off at the discretion of the investigator. Approximately 456 adult patients
      (228 in each treatment group) will participate in this study. Efficacy will be assessed with
      the following measures: PANSS (total score and subscale scores), Clinical Global Impression -
      Severity (CGI-S), Self-rated health status Survey SF-36, and Sleep and daytime drowsiness
      evaluation scale. The parameters related to the total of the actions of the body to keep it
      alive (metabolic endpoints) will be assessed with the following: ratio of blood lipids to
      blood good cholesterol concentrations (TG:HDL ratio) (for this primary evaluation, plasma
      fasting lipids and good cholesterol concentrations will be measured), fasting plasma insulin
      and fasting plasma glucose, plasma glucose and insulin concentrations before and after a 75
      gram oral glucose tolerance test (OGTT) to asses insulin sensitivity and changes in insulin
      secretion, fasting good cholesterol, lipids, and glucose levels for the determination of new
      onset or presence of metabolic syndrome during treatment according to criteria of the Third
      Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation,
      and Treatment of High Blood Cholesterol in Adults (NCEP/ATPIII criteria), weight,
      Body-Mass-Index and waist circumference for the determination of new onset or presence of a
      medical condition associated with abdominal obesity, abnormalities in glucose, lipid and
      cholesterol metabolism, and elevated blood pressure that increases the risk of cardiovascular
      disease and type 2 diabetes (metabolic syndrome) during treatment according to NCEP/ATP III
      criteria. All patients who receive trial medication (paliperidone ER or olanzapine) at least
      once will be included in the analysis of the demographic and baseline characteristic data. 2
      dosage levels of paliperidone ER (6 or 9mg per day) and 2 of olanzapine (10 and 15mg per day)
      are available to the patients. Throughout the study flexible dosing is allowed based on the
      investigator's discretion. Study medication is to be taken in the morning orally, with water.
      A study treatment period of 6 months is planned for all patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to End Point in the Triglycerides (TG) to High Density Lipoprotein (HDL) Ratio (TG:HDL Ratio)</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>Plasma fasting TG and HDL concentrations were measured to determine the TG:HDL ratio.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End Point in Triglycerides</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>The TG level was assessed under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End Point in High Density Lipoprotein</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>The HDL level was assessed under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End Point in Total Cholesterol</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>The total cholesterol level was assessed under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End Point in Low Density Lipoprotein Cholesterol (Friedwald QT)</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>The level of low density lipoprotein cholesterol was calculated using the Friedwald QT formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End Point in Converted Insulin</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>The insulin level was assessed under fasted conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End Point in Fasting Glucose</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End Point in Homeostatic Model Assessment of Beta-cell Function (HOMA-%B)</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>HOMA-%B is used to assess beta-cell function. HOMA-%B is a dimensionless measure of beta-cell function (higher values present increased insulin secretion for a given glucose level).
HOMA-%B is normalized so that lean, healthy individuals will have values of HOMA-%B close to 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End Point in Homeastatic Model Assessment of Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>HOMA-IR is used to assess insulin resistance (IR). HOMA-IR is a dimensionless measure of insulin resistance (higher values present more insulin resistance. HOMA-IR are normalized so that lean, healthy individuals will have values of HOMA-IR close to 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Meeting the Criteria for Type 2 Diabetes Mellitus During Follow-up</measure>
    <time_frame>6 months</time_frame>
    <description>Fasting plasma glucose ≥126 mg/dL or 2-hour post-load plasma glucose ≥200 mg/dL during an oral glucose tolerance test (OGTT) or initiated use of glucose-lowering agents during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Onset of Impaired Glucose Tolerance</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>Glucose ≥140 mg/dL, &lt;200 mg/dL after a 75g OGTT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Impaired Fasting Glucose</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>Post-baseline glucose level under fasted conditions ≥100 mg/dL but &lt;126 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at End Point of the Insulinogenic Index</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>The insulinogenic index, defined as (insulin at 30 min - insulin at 0)/(glucose at 30 min [G(30)] - glucose at 0 [G(0)]) was used as a measure of early insulin secretion in response to the OGTT. Because the index is undefined when G(30)-G(0)=0, and poorly defined when G(30)-G(0)&lt;0, the index was only calculated when G(30)&gt;G(0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at End Point of Mari-Type Analysis of Glucose Sensitivity for Insulin</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>As another measure of beta-cell function, the relationship between plasma insulin and glucose concentrations during the OGTT was calculated using a simplified version of the method described by Mari et al. (Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90:4888-4894.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at End Point in Body Weight</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>Patients were weighed lightly clothed. The same amount of clothing had to be worn each time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at End Point in Body Mass Index (BMI)</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>BMI is calculated by dividing the body weight (in kg) by the square of height (in meters).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at End Point in Waist Circumference</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>Patients had to be instructed to stand erect with abdomen relaxed, arms at sides, feet together, and weight divided equally over both legs. The tape measure was placed around the bare abdomen midway between the palpated iliac crest and the palpated lowest rib margin in the left and right mid-axillary lines. A nonstretchable tape was evenly placed around the natural waist covering the left and right natural-waist marks. The measurement scale had to face outward, and there could not be any twists in the tape. The tape had to be just touching the skin but not compressing the soft tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients First Meeting the NCEP/ATP III Criteria for Metabolic Syndrome During Follow-up</measure>
    <time_frame>6 months</time_frame>
    <description>Metabolic syndrome is defined according the Third Report of the National Cholesterol Education Program Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP/ATPIII) of which 3 out of 5 criteria must be met:
waist circumference men &gt; 102 cm; waist circumference women &gt; 88 cm
TG ≥ 150 mg/dL
HDL cholesterol men &lt;40 mg/dL; HDL cholesterol women &lt;50 mg/dL
Blood pressure systolic ≥ 130 mmHg; Blood pressure diastolic ≥ 85 mmHg
Fasting glucose ≥ 110 mg /dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End Point in Total Positive and Negative Syndrome Scale Score (PANSS)</measure>
    <time_frame>Baseline to End Point (up to 6 months)</time_frame>
    <description>PANSS is an investigator-rated 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The PANSS provided a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a scale of 1 (absent) to 7 (extreme).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">462</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paliperidone ER 6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olanzapine 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paliperidone ER</intervention_name>
    <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient meets the DSM-IV criteria for schizophrenia

          -  Patient has a PANSS total score at screening of 60 to 100, inclusive

          -  Patient must, in the opinion of the investigator, benefit from treatment with
             paliperidone ER or olanzapine

          -  Patients on lipid-lowering therapy must be on a stable dose for at least 4 weeks for
             statins, niacin, ezetimibe and resins or for at least 12 weeks for fibrates

          -  Female patients must be postmenopausal (for at least 1 year), surgically sterile,
             abstinent, or, if sexually active, be practicing and effective method of birth control
             (e.g. prescription oral contraceptives, contraceptive injections, intrauterine device,
             double-barrier method, contraceptive patch, male partner sterilization) before entry
             and throughout the study

          -  Women of child-bearing potential must have a negative urine pregnancy test at
             screening

          -  Patient is healthy on the basis of a physical examination and vital signs at screening

        Exclusion Criteria:

          -  Patient has previously been treated with paliperidone ER, olanzapine, or clozapine
             within the past 6 months or has never been treated with an antipsychotic before

          -  Treatment with a depot antipsychotic within the past 3 months

          -  Treatment with a mood stabilizer or a recently initiated antidepressant (&lt;= 3 months)

          -  Patient has abnormal fasting plasma glucose (&gt; 126 mg/dL) or fasting triglycerides
             (TG) levels (&gt; 400 mg/dL) at screening

          -  Relevant history of any significant and/or unstable cardiovascular, respiratory,
             neurologic (including seizures or significant cerebrovascular), renal, hepatic,
             endocrine, or immunologic diseases, including recent or present clinically relevant
             laboratory abnormalities (as deemed by the investigator)

          -  History or current symptoms of tardive dyskinesia

          -  History of neuroleptic malignant syndrome

          -  Pregnant or breast-feeding female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen-Cilag International NV Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen-Cilag International NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Banfaig 2 District</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pärnu N/A</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu N/A</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montberon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jelgava</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liepaja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sigulda</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strenci</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tg Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Michalovce</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vic</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zamora</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Jordan</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>Lithuania</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=50&amp;filename=CR013189_CSR.pdf</url>
    <description>A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <results_first_submitted>April 7, 2010</results_first_submitted>
  <results_first_submitted_qc>July 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2010</results_first_posted>
  <last_update_submitted>April 24, 2014</last_update_submitted>
  <last_update_submitted_qc>April 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paliperidone ER</keyword>
  <keyword>Olanzapine</keyword>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Three subjects of the 462 enrolled did not receive study medication and were excluded from analysis: 2 subjects were randomized by mistake by the investigator and 1 subject withdrew consent before first intake of study medication. The ITT population consisted of 459 subjects who took at least one dose of study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Paliperidone Extended Release (ER)</title>
          <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Olanzapine</title>
          <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="239"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paliperidone ER</title>
          <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Olanzapine</title>
          <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="239"/>
            <count group_id="B2" value="220"/>
            <count group_id="B3" value="459"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="11.1"/>
                    <measurement group_id="B2" value="37.5" spread="11.4"/>
                    <measurement group_id="B3" value="38.2" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="6.31"/>
                    <measurement group_id="B2" value="27.0" spread="5.73"/>
                    <measurement group_id="B3" value="26.9" spread="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.2" spread="14.4"/>
                    <measurement group_id="B2" value="93.3" spread="15.6"/>
                    <measurement group_id="B3" value="92.7" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.9" spread="17.0"/>
                    <measurement group_id="B2" value="77.9" spread="16.5"/>
                    <measurement group_id="B3" value="76.9" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End Point in the Triglycerides (TG) to High Density Lipoprotein (HDL) Ratio (TG:HDL Ratio)</title>
        <description>Plasma fasting TG and HDL concentrations were measured to determine the TG:HDL ratio.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>The primary end point analysis set consisted of 413 patients, i.e., all patients who received study medication at least once and had baseline and post-baseline TG and HDL data. Data of patients with missing TG or HDL values or who started or changed lipid-lowering medication during the trial were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End Point in the Triglycerides (TG) to High Density Lipoprotein (HDL) Ratio (TG:HDL Ratio)</title>
          <description>Plasma fasting TG and HDL concentrations were measured to determine the TG:HDL ratio.</description>
          <population>The primary end point analysis set consisted of 413 patients, i.e., all patients who received study medication at least once and had baseline and post-baseline TG and HDL data. Data of patients with missing TG or HDL values or who started or changed lipid-lowering medication during the trial were excluded from analysis.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="1.10"/>
                    <measurement group_id="O2" value="0.42" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on available data it was estimated that in the paliperidone ER group the TG:HDL ratio would decrease with 0.15 and that the TG:HDL ratio would increase with 0.25 in the olanzapine group. The common SD of the change was estimated to be 1.4. A sample size of 205 patients in each treatment arm had 80% power to detect a difference of 0.4 in change of TG:HDL ratio after 6 months of treatment in favor of paliperidone ER treatment (Wilcoxon two-sample test with 0.05 two-sided significance level).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group comparison of the change from baseline at end point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4718</p_value>
            <method>Wilcoxon signed rank test</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline at end point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wilcoxon signed rank test</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End Point in Triglycerides</title>
        <description>The TG level was assessed under fasted conditions.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End Point in Triglycerides</title>
          <description>The TG level was assessed under fasted conditions.</description>
          <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.77"/>
                    <measurement group_id="O2" value="0.36" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline to end point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9143</p_value>
            <method>Wilcoxon signed rank test</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline to end point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon signed rank test</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End Point in High Density Lipoprotein</title>
        <description>The HDL level was assessed under fasted conditions.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End Point in High Density Lipoprotein</title>
          <description>The HDL level was assessed under fasted conditions.</description>
          <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.25"/>
                    <measurement group_id="O2" value="-0.04" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0050</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline to end point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4454</p_value>
            <method>Wilcoxon signed rank test</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline to end point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>Wilcoxon signed rank test</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End Point in Total Cholesterol</title>
        <description>The total cholesterol level was assessed under fasted conditions.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>Safety data were analyzed using the Intent-to-Treat (ITT) analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End Point in Total Cholesterol</title>
          <description>The total cholesterol level was assessed under fasted conditions.</description>
          <population>Safety data were analyzed using the Intent-to-Treat (ITT) analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0263" spread="0.7841"/>
                    <measurement group_id="O2" value="0.2886" spread="0.8493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End Point in Low Density Lipoprotein Cholesterol (Friedwald QT)</title>
        <description>The level of low density lipoprotein cholesterol was calculated using the Friedwald QT formula.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>Safety data were analyzed using the ITT analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End Point in Low Density Lipoprotein Cholesterol (Friedwald QT)</title>
          <description>The level of low density lipoprotein cholesterol was calculated using the Friedwald QT formula.</description>
          <population>Safety data were analyzed using the ITT analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0029" spread="0.6726"/>
                    <measurement group_id="O2" value="0.1892" spread="0.7361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End Point in Converted Insulin</title>
        <description>The insulin level was assessed under fasted conditions.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>Safety data were analyzed using the ITT analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End Point in Converted Insulin</title>
          <description>The insulin level was assessed under fasted conditions.</description>
          <population>Safety data were analyzed using the ITT analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7397" spread="89.9776"/>
                    <measurement group_id="O2" value="17.2327" spread="84.6255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0272</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End Point in Fasting Glucose</title>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>Safety data were analyzed using the ITT analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End Point in Fasting Glucose</title>
          <population>Safety data were analyzed using the ITT analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2071" spread="0.4953"/>
                    <measurement group_id="O2" value="0.0769" spread="0.4781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1892</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End Point in Homeostatic Model Assessment of Beta-cell Function (HOMA-%B)</title>
        <description>HOMA-%B is used to assess beta-cell function. HOMA-%B is a dimensionless measure of beta-cell function (higher values present increased insulin secretion for a given glucose level).
HOMA-%B is normalized so that lean, healthy individuals will have values of HOMA-%B close to 100%.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post baseline data for the particular secondary efficacy parameter under discussion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End Point in Homeostatic Model Assessment of Beta-cell Function (HOMA-%B)</title>
          <description>HOMA-%B is used to assess beta-cell function. HOMA-%B is a dimensionless measure of beta-cell function (higher values present increased insulin secretion for a given glucose level).
HOMA-%B is normalized so that lean, healthy individuals will have values of HOMA-%B close to 100%.</description>
          <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post baseline data for the particular secondary efficacy parameter under discussion.</population>
          <units>dimensionless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.54" spread="85.91"/>
                    <measurement group_id="O2" value="18.82" spread="147.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0325</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End Point in Homeastatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
        <description>HOMA-IR is used to assess insulin resistance (IR). HOMA-IR is a dimensionless measure of insulin resistance (higher values present more insulin resistance. HOMA-IR are normalized so that lean, healthy individuals will have values of HOMA-IR close to 1.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End Point in Homeastatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>HOMA-IR is used to assess insulin resistance (IR). HOMA-IR is a dimensionless measure of insulin resistance (higher values present more insulin resistance. HOMA-IR are normalized so that lean, healthy individuals will have values of HOMA-IR close to 1.</description>
          <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
          <units>dimensionless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="5.39"/>
                    <measurement group_id="O2" value="0.43" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1117</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Meeting the Criteria for Type 2 Diabetes Mellitus During Follow-up</title>
        <description>Fasting plasma glucose ≥126 mg/dL or 2-hour post-load plasma glucose ≥200 mg/dL during an oral glucose tolerance test (OGTT) or initiated use of glucose-lowering agents during the course of the study.</description>
        <time_frame>6 months</time_frame>
        <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement.Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Meeting the Criteria for Type 2 Diabetes Mellitus During Follow-up</title>
          <description>Fasting plasma glucose ≥126 mg/dL or 2-hour post-load plasma glucose ≥200 mg/dL during an oral glucose tolerance test (OGTT) or initiated use of glucose-lowering agents during the course of the study.</description>
          <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement.Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6346</p_value>
            <method>Fisher Exact</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Onset of Impaired Glucose Tolerance</title>
        <description>Glucose ≥140 mg/dL, &lt;200 mg/dL after a 75g OGTT.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement.Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Onset of Impaired Glucose Tolerance</title>
          <description>Glucose ≥140 mg/dL, &lt;200 mg/dL after a 75g OGTT.</description>
          <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement.Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Impaired Fasting Glucose</title>
        <description>Post-baseline glucose level under fasted conditions ≥100 mg/dL but &lt;126 mg/dL.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Impaired Fasting Glucose</title>
          <description>Post-baseline glucose level under fasted conditions ≥100 mg/dL but &lt;126 mg/dL.</description>
          <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6770</p_value>
            <method>Fisher Exact</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at End Point of the Insulinogenic Index</title>
        <description>The insulinogenic index, defined as (insulin at 30 min - insulin at 0)/(glucose at 30 min [G(30)] - glucose at 0 [G(0)]) was used as a measure of early insulin secretion in response to the OGTT. Because the index is undefined when G(30)-G(0)=0, and poorly defined when G(30)-G(0)&lt;0, the index was only calculated when G(30)&gt;G(0).</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at End Point of the Insulinogenic Index</title>
          <description>The insulinogenic index, defined as (insulin at 30 min - insulin at 0)/(glucose at 30 min [G(30)] - glucose at 0 [G(0)]) was used as a measure of early insulin secretion in response to the OGTT. Because the index is undefined when G(30)-G(0)=0, and poorly defined when G(30)-G(0)&lt;0, the index was only calculated when G(30)&gt;G(0).</description>
          <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
          <units>pM/mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="173.46"/>
                    <measurement group_id="O2" value="33.78" spread="259.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1308</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at End Point of Mari-Type Analysis of Glucose Sensitivity for Insulin</title>
        <description>As another measure of beta-cell function, the relationship between plasma insulin and glucose concentrations during the OGTT was calculated using a simplified version of the method described by Mari et al. (Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90:4888-4894.).</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at End Point of Mari-Type Analysis of Glucose Sensitivity for Insulin</title>
          <description>As another measure of beta-cell function, the relationship between plasma insulin and glucose concentrations during the OGTT was calculated using a simplified version of the method described by Mari et al. (Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90:4888-4894.).</description>
          <population>The secondary end point analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
          <units>pM/mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.63" spread="79.53"/>
                    <measurement group_id="O2" value="17.28" spread="94.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3358</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at End Point in Body Weight</title>
        <description>Patients were weighed lightly clothed. The same amount of clothing had to be worn each time.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>Safety data were analyzed using the ITT analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at End Point in Body Weight</title>
          <description>Patients were weighed lightly clothed. The same amount of clothing had to be worn each time.</description>
          <population>Safety data were analyzed using the ITT analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="4.57"/>
                    <measurement group_id="O2" value="3.81" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline to end point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Wilcoxon signed rank test</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline to end point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wilcoxon signed rank test</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at End Point in Body Mass Index (BMI)</title>
        <description>BMI is calculated by dividing the body weight (in kg) by the square of height (in meters).</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at End Point in Body Mass Index (BMI)</title>
          <description>BMI is calculated by dividing the body weight (in kg) by the square of height (in meters).</description>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="1.59"/>
                    <measurement group_id="O2" value="1.32" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at End Point in Waist Circumference</title>
        <description>Patients had to be instructed to stand erect with abdomen relaxed, arms at sides, feet together, and weight divided equally over both legs. The tape measure was placed around the bare abdomen midway between the palpated iliac crest and the palpated lowest rib margin in the left and right mid-axillary lines. A nonstretchable tape was evenly placed around the natural waist covering the left and right natural-waist marks. The measurement scale had to face outward, and there could not be any twists in the tape. The tape had to be just touching the skin but not compressing the soft tissue.</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>Safety data were analyzed using the ITT analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at End Point in Waist Circumference</title>
          <description>Patients had to be instructed to stand erect with abdomen relaxed, arms at sides, feet together, and weight divided equally over both legs. The tape measure was placed around the bare abdomen midway between the palpated iliac crest and the palpated lowest rib margin in the left and right mid-axillary lines. A nonstretchable tape was evenly placed around the natural waist covering the left and right natural-waist marks. The measurement scale had to face outward, and there could not be any twists in the tape. The tape had to be just touching the skin but not compressing the soft tissue.</description>
          <population>Safety data were analyzed using the ITT analysis set for safety and consisted of 459 patients, i.e., all patients who received study medication at least once and provided any post-baseline safety data. Changes from baseline could only be calculated for patients with paired data.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="5.39"/>
                    <measurement group_id="O2" value="3.38" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients First Meeting the NCEP/ATP III Criteria for Metabolic Syndrome During Follow-up</title>
        <description>Metabolic syndrome is defined according the Third Report of the National Cholesterol Education Program Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP/ATPIII) of which 3 out of 5 criteria must be met:
waist circumference men &gt; 102 cm; waist circumference women &gt; 88 cm
TG ≥ 150 mg/dL
HDL cholesterol men &lt;40 mg/dL; HDL cholesterol women &lt;50 mg/dL
Blood pressure systolic ≥ 130 mmHg; Blood pressure diastolic ≥ 85 mmHg
Fasting glucose ≥ 110 mg /dL</description>
        <time_frame>6 months</time_frame>
        <population>The secondary endpoint analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. In this case, the total number of patients in the analysis set depends on the number of patients without metabolic syndrome at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients First Meeting the NCEP/ATP III Criteria for Metabolic Syndrome During Follow-up</title>
          <description>Metabolic syndrome is defined according the Third Report of the National Cholesterol Education Program Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP/ATPIII) of which 3 out of 5 criteria must be met:
waist circumference men &gt; 102 cm; waist circumference women &gt; 88 cm
TG ≥ 150 mg/dL
HDL cholesterol men &lt;40 mg/dL; HDL cholesterol women &lt;50 mg/dL
Blood pressure systolic ≥ 130 mmHg; Blood pressure diastolic ≥ 85 mmHg
Fasting glucose ≥ 110 mg /dL</description>
          <population>The secondary endpoint analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. In this case, the total number of patients in the analysis set depends on the number of patients without metabolic syndrome at baseline.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0230</p_value>
            <method>Fisher Exact</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End Point in Total Positive and Negative Syndrome Scale Score (PANSS)</title>
        <description>PANSS is an investigator-rated 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The PANSS provided a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a scale of 1 (absent) to 7 (extreme).</description>
        <time_frame>Baseline to End Point (up to 6 months)</time_frame>
        <population>The secondary endpoint analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone ER</title>
            <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Olanzapine</title>
            <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End Point in Total Positive and Negative Syndrome Scale Score (PANSS)</title>
          <description>PANSS is an investigator-rated 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The PANSS provided a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a scale of 1 (absent) to 7 (extreme).</description>
          <population>The secondary endpoint analysis set included all patients who received study medication at least once and provided ≥1 post-baseline efficacy measurement. Therefore, the total number of patients in the analysis set depends on the number of patients having post-baseline data for the particular secondary efficacy parameter under discussion.</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.50" spread="15.86"/>
                    <measurement group_id="O2" value="-16.60" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Testing non-inferiority of the paliperidone ER treatment group compared to the olanzapine treatment group, with regard to change versus baseline at end point of the total PANSS was done by means of Schuirmann’s test. A difference of 6 points in change versus baseline on the total PANSS was considered to be a minimum clinically relevant difference.The null hypothesis is that there is no difference between paliperidone and olanzapine in change in TG:HDL ratio from baseline to endpoint.</non_inferiority_desc>
            <p_value>0.0242</p_value>
            <method>Schuirmann</method>
            <method_desc>The null hypothesis of non-equivalence was rejected and equivalence to within the specified equivalence bounds could be claimed.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline to end point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon signed rank test</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within-group change from baseline to end point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon signed rank test</method>
            <method_desc>This test was interpreted at the 5% significance level (2-tailed).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From informed consent up to 6 months (+/- 7 days) of treatment. In case subjects had discontinued before completing treatment, the last data were obtained at the early discontinuation visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Paliperidone ER</title>
          <description>6-mg or 9-mg tablet once daily flexible dosing for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Olanzapine</title>
          <description>10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Psychiatric symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Waist circumference increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Tension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Galactorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open-label design</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>EMEA Therapeutic Area Leader CNS</name_or_title>
      <organization>Janssen-Cilag Germany</organization>
      <phone>+492137955153</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

